EP3615072A1 - Diagnostic method - Google Patents
Diagnostic methodInfo
- Publication number
- EP3615072A1 EP3615072A1 EP18746103.3A EP18746103A EP3615072A1 EP 3615072 A1 EP3615072 A1 EP 3615072A1 EP 18746103 A EP18746103 A EP 18746103A EP 3615072 A1 EP3615072 A1 EP 3615072A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- binding molecule
- subset
- cells
- autonomously
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002405 diagnostic procedure Methods 0.000 title claims abstract description 14
- 108091008875 B cell receptors Proteins 0.000 claims abstract description 99
- 230000027455 binding Effects 0.000 claims abstract description 60
- 238000009739 binding Methods 0.000 claims abstract description 59
- 239000012634 fragment Substances 0.000 claims abstract description 14
- 230000003211 malignant effect Effects 0.000 claims abstract description 14
- 208000012526 B-cell neoplasm Diseases 0.000 claims abstract description 5
- 108020003175 receptors Proteins 0.000 claims description 31
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 29
- 238000000034 method Methods 0.000 claims description 19
- 210000004408 hybridoma Anatomy 0.000 claims description 14
- 238000004519 manufacturing process Methods 0.000 claims description 9
- 239000012528 membrane Substances 0.000 claims description 9
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 8
- 230000008569 process Effects 0.000 claims description 6
- 230000003053 immunization Effects 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- 238000003745 diagnosis Methods 0.000 claims description 3
- 239000007850 fluorescent dye Substances 0.000 claims description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 13
- 206010028980 Neoplasm Diseases 0.000 abstract description 12
- 201000011510 cancer Diseases 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 62
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 35
- 102000005962 receptors Human genes 0.000 description 30
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 28
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 26
- 239000006228 supernatant Substances 0.000 description 13
- 201000010099 disease Diseases 0.000 description 12
- 239000013598 vector Substances 0.000 description 12
- 238000002965 ELISA Methods 0.000 description 9
- 125000000174 L-prolyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])[C@@]1([H])C(*)=O 0.000 description 9
- 230000015572 biosynthetic process Effects 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 9
- 230000018109 developmental process Effects 0.000 description 8
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 8
- 208000032839 leukemia Diseases 0.000 description 8
- 238000010561 standard procedure Methods 0.000 description 8
- 102100035634 B-cell linker protein Human genes 0.000 description 7
- 101001061851 Homo sapiens V(D)J recombination-activating protein 2 Proteins 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 7
- 102100029591 V(D)J recombination-activating protein 2 Human genes 0.000 description 7
- 238000011161 development Methods 0.000 description 7
- 210000001948 pro-b lymphocyte Anatomy 0.000 description 7
- 241001529936 Murinae Species 0.000 description 6
- 230000004913 activation Effects 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 101000803266 Homo sapiens B-cell linker protein Proteins 0.000 description 5
- 101000840267 Homo sapiens Immunoglobulin lambda-like polypeptide 1 Proteins 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 210000001185 bone marrow Anatomy 0.000 description 5
- 230000009826 neoplastic cell growth Effects 0.000 description 5
- 230000006798 recombination Effects 0.000 description 5
- 238000005215 recombination Methods 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- 102100029616 Immunoglobulin lambda-like polypeptide 1 Human genes 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 230000008707 rearrangement Effects 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 3
- 206010025323 Lymphomas Diseases 0.000 description 3
- 102000001183 RAG-1 Human genes 0.000 description 3
- 108060006897 RAG1 Proteins 0.000 description 3
- 108010004469 allophycocyanin Proteins 0.000 description 3
- 239000007853 buffer solution Substances 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 239000000975 dye Substances 0.000 description 3
- 238000002649 immunization Methods 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 230000009870 specific binding Effects 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- 206010000830 Acute leukaemia Diseases 0.000 description 2
- 101710083670 B-cell linker protein Proteins 0.000 description 2
- 208000003950 B-cell lymphoma Diseases 0.000 description 2
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 2
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 2
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 2
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 2
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 2
- 108010052285 Membrane Proteins Proteins 0.000 description 2
- 102000018697 Membrane Proteins Human genes 0.000 description 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 2
- 229920002873 Polyethylenimine Polymers 0.000 description 2
- 108010018324 Surrogate Immunoglobulin Light Chains Proteins 0.000 description 2
- 102000002663 Surrogate Immunoglobulin Light Chains Human genes 0.000 description 2
- 230000001363 autoimmune Effects 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 208000024207 chronic leukemia Diseases 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 230000013595 glycosylation Effects 0.000 description 2
- 238000006206 glycosylation reaction Methods 0.000 description 2
- 239000005090 green fluorescent protein Substances 0.000 description 2
- 230000003394 haemopoietic effect Effects 0.000 description 2
- 210000000777 hematopoietic system Anatomy 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000004324 lymphatic system Anatomy 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 230000035800 maturation Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 229960003347 obinutuzumab Drugs 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 238000007480 sanger sequencing Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 241000251468 Actinopterygii Species 0.000 description 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
- 108010083359 Antigen Receptors Proteins 0.000 description 1
- 102000006306 Antigen Receptors Human genes 0.000 description 1
- 108010012919 B-Cell Antigen Receptors Proteins 0.000 description 1
- 102000019260 B-Cell Antigen Receptors Human genes 0.000 description 1
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 1
- 208000011691 Burkitt lymphomas Diseases 0.000 description 1
- 108091033409 CRISPR Proteins 0.000 description 1
- 238000010354 CRISPR gene editing Methods 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 208000015943 Coeliac disease Diseases 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 208000028399 Critical Illness Diseases 0.000 description 1
- 108010087819 Fc receptors Proteins 0.000 description 1
- 102000009109 Fc receptors Human genes 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 108010079585 Immunoglobulin Subunits Proteins 0.000 description 1
- 102000012745 Immunoglobulin Subunits Human genes 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102000005431 Molecular Chaperones Human genes 0.000 description 1
- 108010006519 Molecular Chaperones Proteins 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 241000233805 Phoenix Species 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 230000010799 Receptor Interactions Effects 0.000 description 1
- 101710120037 Toxin CcdB Proteins 0.000 description 1
- 102000012883 Tumor Necrosis Factor Ligand Superfamily Member 14 Human genes 0.000 description 1
- 108010065158 Tumor Necrosis Factor Ligand Superfamily Member 14 Proteins 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 102000035181 adaptor proteins Human genes 0.000 description 1
- 108091005764 adaptor proteins Proteins 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000003302 anti-idiotype Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000002567 autonomic effect Effects 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000012503 blood component Substances 0.000 description 1
- 230000003185 calcium uptake Effects 0.000 description 1
- 208000035269 cancer or benign tumor Diseases 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 239000000306 component Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 229940039227 diagnostic agent Drugs 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 239000012645 endogenous antigen Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000001400 expression cloning Methods 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 108091006047 fluorescent proteins Proteins 0.000 description 1
- 102000034287 fluorescent proteins Human genes 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000002439 hemostatic effect Effects 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- PNDZEEPOYCVIIY-UHFFFAOYSA-N indo-1 Chemical compound CC1=CC=C(N(CC(O)=O)CC(O)=O)C(OCCOC=2C(=CC=C(C=2)C=2N=C3[CH]C(=CC=C3C=2)C(O)=O)N(CC(O)=O)CC(O)=O)=C1 PNDZEEPOYCVIIY-UHFFFAOYSA-N 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 102000027411 intracellular receptors Human genes 0.000 description 1
- 108091008582 intracellular receptors Proteins 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 210000003519 mature b lymphocyte Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 229960002450 ofatumumab Drugs 0.000 description 1
- 210000000287 oocyte Anatomy 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000001991 pathophysiological effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 229960004641 rituximab Drugs 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 229940043517 specific immunoglobulins Drugs 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 210000002536 stromal cell Anatomy 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39566—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against immunoglobulins, e.g. anti-idiotypic antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3061—Blood cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
Definitions
- the present invention relates to the field of production, identification and selection of antibodies or fragments thereof, as well as their use in the diagnosis of cancers, in particular malignant B-cell neoplasms.
- Malignant B-cell neoplasms are commonly referred to as malignant diseases of the hematopoietic or lymphatic system. They include diseases such as leukemia and count in a broader sense to the cancers.
- Leukemias are characterized by a greatly increased production of dysfunctional white blood cell precursor cells, which are also called leukemia cells. These cells spread in the bone marrow, displace there the usual blood formation and accumulate as a rule "also greatly increased in the peripheral blood. They can infiltrate the liver, spleen, lymph nodes and other organs, thereby impairing their function.
- the disruption of blood formation results in a decrease in normal blood components, which may cause anemia due to lack of oxygen-carrying red blood cells, lack of hemostatic platelets, and a lack of mature, functional white blood cells.
- Acute leukemias are life-threatening diseases that, if left untreated, can lead to death within a few weeks to months.
- Chronic leukemias usually run over several years and are often symptom poor in the initial stage.
- AML acute myeloid leukemia
- CML chronic myeloid leukemia
- ALL acute lymphoblastic leukemia
- CLL chronic lymphocytic leukemia
- leukemias are treated as part of chemotherapy.
- Newer forms of therapy are increasingly relying on the use of monoclonal antibodies such.
- GA101 bisnutuzumab
- rituximab and ofatumumab acts as a CD20 antibody and is used to treat chronic lymphocytic leukemia (CLL).
- CLL chronic lymphocytic leukemia
- Other malignant diseases of the hematopoietic or lymphatic system malignant B-cell neoplasms
- lymphomas such as lymphoma.
- Hodgkin's lymphoma and B-cell variants of non-Hodgkin's lymphoma are malignant diseases of the hematopoietic or lymphatic system.
- antibodies are generated against receptors, then usually.
- these hybridoma cells produce antibodies that are then tested in cell systems by ELISA or expressed receptors, using established cell lines because they are the only ones that are easily cultivated
- Antibodies can be generated that bind relatively specifically to a specific receptor type (eg, anti-IgGl, anti-IgE), but often cross-react with other receptors or other epitopes.
- BCR antibodies For a diagnostic application of BCR antibodies, it is usually not sufficient to use only one antibody against the BCR in general, since such a broadband use can lead to false positive results. Rather, it would be desirable to provide an antibody that selectively binds to a receptor that has (pathophysiological) activation, particularly autonomous activation. Such an antibody is not known in the art and a Process for its preparation or production by selection does not exist.
- the object of the present invention is therefore to provide alternative concepts and means such as in particular alternative antibodies for diagnostic use, which overcome the existing problems of the prior art.
- neoplasia generally refers to a regeneration of body tissue, which is a malignant or malignant manifestation of malignant neoplasia, malignant B-cell neoplasia thus being a malignant and uncontrolled neoplasm of B cells, these being Conceptuality affects all B-cell associated cancers such as leukemias and B-cell lymphomas alike.
- biological binding molecules herein are meant, for example, but not limited to, antibodies including fusion proteins
- an antibody is selected from the group consisting of an IgG antibody, an IgM antibody, a humanized IgG antibody, and a human
- a binding molecule may also be provided in the form of a functional fragment of the entire antibody, eg a Fab fragment
- a binding molecule may also comprise further regions or additional entities, the use of which in the context of diagnostic These may be fluorescence dyes (eg: FITC, R-phycoerythrin (R-PE), allophycocyanin (APC)) or biotin as well as other substances known to the person skilled in the art using flow cytometry.Furthermore, a binding molecule may be immunohistochemized Mixer method also together with substrate-converting enzymes (e.g. HRP). Furthermore, fusion proteins can also be provided for diagnostic purposes in which for detection
- B-cell receptor or B-cell receptor complex BCR
- BCR B-cell receptor complex
- the role of the B-cell receptor or B-cell receptor complex (BCR) on the surface of a B-cell is to recognize and bind pathogens, so it can be regarded as a membrane-bound antibody. This binding leads to a conformational change of the BCR, which triggers a signal cascade that ultimately leads to activation of the B cell.
- the BCR is formed in great variety in maturing B cells. The development of B cells occurs in humans and in some other mammals in the bone marrow or fetal liver. The signals necessary for the development program are obtained from the developing lymphocytes of so-called stromal cells.
- B-cell development the formation of a functioning B-cell receptor (the membrane-bound form of the 'antibody') is of crucial importance. Only with this antigen receptor are mature B cells later able to recognize foreign antigens and bind to hostile structures through the formation of corresponding antibodies.
- the antigen specificity of the receptor is determined by the linkage of certain gene segments. The segments are called V, D and J segments, which is why the process is called V (D) J recombination. These segments, which form the antigen-binding part of the B-cell receptor, rearranged.
- the entire receptor consists of two identical light protein chains and two identical heavy protein chains, with the heavy and the light chains each linked together via disulfide bridges.
- VDJ recombination first the V, D and J segments of the heavy chain of the B cell receptor are linked, followed by the V and J segments of the light receptor chain. Only when the genes are successfully rearranged, which is referred to as productive gene rearrangement, the cell can go into the next development step.
- BCR Since the process of generating such a BCR is based on a random assembly of gene segments, it may happen that the newly created BCR recognizes unwanted endogenous structures and thus becomes “permanently activated.” To prevent the emergence of such a "permanently active or activated" BCR There are various body protection mechanisms. However, if these are overcome due to a pathological change in the developing B-cell, it may develop into a malignant or even autoimmune manifesting disease.
- an “autonomously active” or “autonomously activated” BCR is a special type of permanently active BCR. While conventional activation proceeds from an external antigen (see above), the autonomously active BCR results from its interaction with membrane structures on the surface of the same cell. For the clinical picture of CLL, an autonomous activation-triggering interaction between BCRs could be shown, which were located adjacent to each other on the surface of the same cell (M. Dmixen-von Minden et al., Nature 2012). Another example of an autonomously active BCR is the pre-BCR, which is expressed during the development of a B cell as a development check. In addition to the interaction of neighboring receptors (BCR: BCR), an interaction between the receptor and a membrane protein (BCR: membrane protein) can lead to an autonomously active or activated BCR.
- BCR neighboring receptors
- BCR membrane protein
- the solution according to the invention of these problems is based on the surprising finding that are located on tumor cells of patents with CLL B-cell receptors that are autonomously activated or autonomously activated, and that these autonomously active or activated receptors by the presence of common epitopes that in corresponding Receptors from healthy cells of the same patient can not be detected, Marked are. Due to the presence of autonomously active B cell receptors, which are characterized by the occurrence of the abovementioned epitopes, these cells can thus be specifically recognized by an antibody and, if appropriate, treated, so that healthy B cells without this characteristic are not affected as a result which makes the treatment much more specific and with less undesirable side effects.
- modified receptor regions can not be prepared and selected by standard methods. Only after the experimental conditions were adapted in such a way that genetically modified cells whose modified B cell receptors were in a native and activated state were used in binding studies were it possible to obtain suitable antibodies with the desired and required specificity. In other words, it is of essential importance for the solutions proposed according to the invention that the cells used in binding studies for the selection of suitable diagnostic antibodies present their modified regions (epitopes) in largely native and activated form. It turned out that so-called pro- / pre-B cells are particularly suitable because of their physiological constitution.
- the present invention provides diagnostic methods using biological binding molecules in the form of antibodies or functional fragments thereof and a method for producing (identifying and selecting) such binding molecules which selectively binds to the modified epitopes of autonomously active membrane-bound immunoglobulins of B-molecules. Binding cell neoplasia.
- the biological binding proteins selectively bind to such autonomously active B cell receptors on B cells which occur in immunological (eg autoimmune) diseases and are causally related to them (eg allergies, ulcerative colitis, diabetes mellitus Type 1, multiple sclerosis, psoriasis, rheumatic fever, rheumatoid arthritis, celiac disease).
- immunological eg autoimmune
- diseases eg allergies, ulcerative colitis, diabetes mellitus Type 1, multiple sclerosis, psoriasis, rheumatic fever, rheumatoid arthritis, celiac disease.
- each individual B-cell progenitor generates its own and almost unique B-cell receptor (BCR) through the rearrangement of individual gene segments.
- BCR B-cell receptor
- the area of subset 2 relevant for the autonomously active functionality of the receptor is characterized by the amino acid sequences KLTVLRQPKA (SEQ ID NO. 1 ⁇ and VAPGKTAR (SEQ ID NO. 2) of the light chain, while that relevant for the autonomously active functionality of the receptor
- the sequence of subset 4 is defined by the amino acid sequences PTIRRYYYYG (SEQ ID NO: 3) and NHKPSNTKV (SEQ ID NO: 4) of the variable part of the heavy chain
- the sequences used for generating the murine antibodies in the immunization for the subsets 2 and 4 are given in SEQ ID Nos.
- SEQ ID NO: 17 contains another target sequence or epitope Specified specificity for the variable part of the heavy chain of a BCR of the subset 4.
- OSs 3 and 4 represent the sequence according to SEQ ID NO.
- the methods used until this finding included not only standard methods such as ELISA and SPR, but also intracellular expression in fibroblasts with an intracellular FACS staining as binding control.
- the binding molecule proposed according to the invention selectively binds to autonomously active or autonomously activated B cell receptors, which are characterized by the presence of structural domains or epitopes (target sequences) and are responsible for the autonomously active or activated state of B cell receptors.
- the selective binding behavior of the binding molecule proposed according to the invention for diagnostic use means that it does not bind to receptors or other membrane structures of B cells that have no structural domain or epitope that are responsible for the autonomously active or activated state of B cells.
- the binding molecule proposed according to the invention does not bind selectively to target sequences of the B cell receptor which are not characteristic for the subset 2 or the subset 4, and in particular not to a B cell receptor which does not contain any of the sequences SEQ ID NOS. 1, 2, 3 and / or 4.
- pro- / pre-B cells derived from Triple Knockout (TKO) mice is particularly well-suited to these receptors, despite the difficult handling and costly recovery be expressed and used in a test system for the identification of these receptors.
- the stage of pro- / pre-B cells is naturally designed to carry out the maturation and selection of BCRs, and the cells of this stage are particularly suitable because of their enzyme endowment (chaperones, etc.), even for "difficult" BCR components fold in and on your surface in sufficient physiologically native form.
- the deletions (knockouts) described below prevent a change in the desired BCR from taking place by recombination or the use of the surrogates light chain ("surrogate light chain").
- Chromatography which is well known to those skilled in the art, care being taken not to denature the antibodies and to detect possible foreign substances such as e.g. To quantitatively remove proteins, pyrogens and toxins.
- the desired antibodies are expressed in systems in which the antibody undergoes glycosylation, in particular human glycosylation.
- Such systems are well known to those skilled in the art and include the use of insect cells (S2 cells), mammalian cells (CHO cells), and, most preferably, human cells such as HEK293T type cells.
- the sufficiently purified antibody may in itself be therapeutically effective, provided that it has an isotype which elicits a specific immune response, e.g. an IgG subtype that leads to an immune response against the tumor via Fc receptors.
- the antibody can also be present as a fragment.
- the fragment to be used is for diagnostic use by coupling to e.g. modified a fluorescent dye, biotin, and / or to an enzymatic subunit in the usual way.
- the antibody is preferably used in standardized methods such as in a
- the antibodies, biological binding molecules or functional fragments thereof proposed for diagnostic purposes have a murine backbone.
- a detection in the flow cytometer is preferably carried out by means of secondary antibodies, or alternatively preferred by means bound directly to the antibodies, biological binding molecules or functional fragments thereof
- a stabilizing salt buffer e.g. a phosphate buffered saline (PBS), as known to those skilled in the art.
- PBS phosphate buffered saline
- a suitable drying form is e.g. Freeze-drying or lyophilization.
- the production and identification of antibodies that bind selectively to the modified B cell receptors has been characterized by major and unforeseen problems.
- the generation of the hybridomas was carried out by standard methods.
- the supernatant from the hybridoma groups was pooled and tested for positive binding events by ELISA (soluble B cell receptors on the ELISA plate). Positive pools were isolated and the individual clones tested. Surprisingly, no positive clones were identified in the ELISA.
- the positive ELISA signals of the Poole subsequently turned out to be unspecific bindings.
- the BCR light chain has now been expressed in fibroblasts. This should ensure the correct folding of the protein bearing the motif (epitope) responsible for the autonomic signal. With these cells were intracellular FACS analyzes performed. No positive clone (antibody) could be identified.
- RAMOS cells human Burkitt lymphoma cell line
- CRISPR CRISPR
- CLL receptor CMV vectors
- pre-BCR Since the pre-BCR is autonomous, this would be proof of an autonomously active receptor. Since a new BCR is cloned into the cell, a pre-BCR is undesirable since it appears on the surface with the desired heavy chain (HC) in conjunction with the undesirable surrogate light chain and the
- the knockout of SLP65 an adapter protein of central importance in the BCR signaling pathway, prevents activation of the TKO cell by a possibly reconstructed BCR.
- the combination of the knockouts of RAG2 or RAG1 and lambda5 leads to a blockade in the transition from the pro-B cell stage to the pre-B cell stage, which is classically characterized by the onset rearrangement of the VDJ heavy chain (HC) segments is. Therefore, they are pro- / pre-B cells.
- the knockout of RAG2 or RAG1 and lambda5 is sufficient. By reconstitution with the inducible SLP65, the activity of the BCR can be measured.
- the method of choice here is the measurement of Ca flux after induction of the SLP65 by means of FACS analysis and the use of a Ca 2+ -dependent dye such as Indo-1.
- the first two knockouts ensured that only the "BCR of interest” was expressed on the surface, and the use of an inducible SLP-65, with which the cells were reconstituted, could characterize the function of the expressed BCRs and thus autonomously active state of the BCRs on the surface prior to selection can be verified.With these cells as the "target”, FACS was now able to identify an antibody that was linked to the modified Area, by which the autonomous activation of the BCR is justified and characterized, specifically binds. And this, although binding to the same type of receptor in RAMOS cells was unsuccessful!
- the cells which carried the "BCR of interest” on the surface were first incubated with the pooled supernatants, and after a few washing steps, the bound antibodies were detected by means of secondary antibodies.TKO cells (TKOs) were used for a specific selection different versions of the "BCR of interest” expressed.
- the selection matrix shown in FIG. 1 is exemplary for the selection of a CLL subset 2 BCR and was used to identify and select positive clones.
- the supernatants of the hybridomas were pooled and measured. The groups that showed binding were singulated and the supernatants of the respective hybridomas tested for binding.
- mice which have a respective knockout for the genes Lambda5, RAG2 and SLP-65 (Dlicken von Minden et al., 2012, Nature 489, p309-313).
- the preparation of such mice is known in the art and belongs to the prior art.
- the mice were extracted after their killing the bone marrow of the femurs.
- the cells thus obtained were then cultured under conditions favoring the survival of pro- / pre-B cells (37 ° C, 7.5% CO2, Iscoves medium, 10% FCS, P / S, murine IL7).
- a FACS sorting was performed as a control, the pro / pre-B cells were sorted and then returned to culture.
- the markers used for this purpose are known to the person skilled in the art.
- the corresponding sequences coding for the heavy (HC) and light (LC) chains were synthesized and then each cloned into a CMV promoter-containing expression vectors. These were incorporated by lipofection into the packaging cell line (Phoenix cell line). After a 36 hour incubation, virus supernatant was removed and used for spinfection of TKO cells. Both the work for the recovery of the supernatants and the spinfection of the TKO are widely known methods and known to the skilled person.
- subset-2 B cell receptors were taken from the corresponding literature (see above).
- Exemplary CLL subset 2 VH and complete LC DNA segments were synthesized by a contract manufacturer in a standard procedure. These were then fused with a murine IgGl constant segment by PCR and transformed into a CMV Vector cloned. The sequence of the final vector was confirmed by Sanger sequencing.
- CLL subsets 2 IgG1 For expression of CLL subsets 2 IgG1, a human cellular expression system based on HEK293T cells was used. For transfection, a polyethyleneimine (PEI) based protocol was used. After several passages, the supernatant was pooled and the medium contained in the pooled cell supernatant was purified by means of Protein G columns. The purity and quality of the soluble Subset-2 IgGl was determined by Western blot.
- PEI polyethyleneimine
- the mRNA was isolated from the individual hybridoma clones, from which cDNA was generated and amplified by means of anchor PCR (Rapid Expression Cloning of human immunoglobulin Fab fragments for the analysis of antigenic specificity of B cell lymphomas and anti-idiotype lymphoma vaccination; Osterroth F, alkane 0, Mackensen A, Lindemann A, fish P, Skerra A, Veelken H., J Immunol Methods 1999 Oct 29; 229 (1-2): 141-53).
- the heavy chain partial sequences corresponding to CDR1, CDR2 and CDR3 according to SEQ ID NO. 9 are in SEQ ID NOS. 11 to 13, while corresponding to CDRl, CDR2 and CDR3 partial sequences of the light chain according to SEQ ID NO. 10 in the SEQ ID NOS. 14 to 16 are shown.
- CLL Subset 4 LC (SEQ ID NO: 8):
- a small amount of peripheral blood was withdrawn from a patient.
- 100 ⁇ of blood was transferred to a reaction vessel and made up with 2 ml of PBS-BSA buffer solution.
- the sample was centrifuged in an Eppendorf 5804 centrifuge at 1500 rpm for a period of five minutes. The supernatant was discarded and the sediment was well mixed.
- the antibody was added. The following surface parameters were stained: 1) CD19-FITC, 2) CD5-PE, and 3) the CLL SubSet-2 Specific Antibody (APC) before incubating for 15 minutes at room temperature in the dark. Thereafter, lysis was initiated and the erythrocytes were lysed.
- APC CLL SubSet-2 Specific Antibody
- the lymphocyte population was selected and labeled in the FSC / SSC blot. For this selection, it was then focused on the CD19-positive B cells and after binding of the Subset-2 specific antibody analyzed.
- Figure 2 shows an example of such an analysis using the example of the use of the subset-2-specific antibody.
- the CD19 positive B cells were selected for further analysis (left panel). These were then examined for binding of the specific antibody (right panel).
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Hospice & Palliative Care (AREA)
- General Physics & Mathematics (AREA)
- Physics & Mathematics (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Description
Claims
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP17001167 | 2017-07-07 | ||
EP17001166 | 2017-07-07 | ||
EP18162666.4A EP3424527A1 (en) | 2017-07-07 | 2018-03-19 | Diagnostic method |
PCT/EP2018/068316 WO2019008128A1 (en) | 2017-07-07 | 2018-07-05 | Diagnostic method |
Publications (1)
Publication Number | Publication Date |
---|---|
EP3615072A1 true EP3615072A1 (en) | 2020-03-04 |
Family
ID=64500047
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP18162666.4A Withdrawn EP3424527A1 (en) | 2017-07-07 | 2018-03-19 | Diagnostic method |
EP18162672.2A Withdrawn EP3424528A1 (en) | 2017-07-07 | 2018-03-19 | Biologic binding molecules |
EP18746103.3A Pending EP3615072A1 (en) | 2017-07-07 | 2018-07-05 | Diagnostic method |
EP18746104.1A Pending EP3615073A1 (en) | 2017-07-07 | 2018-07-05 | Biological binding molecule |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP18162666.4A Withdrawn EP3424527A1 (en) | 2017-07-07 | 2018-03-19 | Diagnostic method |
EP18162672.2A Withdrawn EP3424528A1 (en) | 2017-07-07 | 2018-03-19 | Biologic binding molecules |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP18746104.1A Pending EP3615073A1 (en) | 2017-07-07 | 2018-07-05 | Biological binding molecule |
Country Status (5)
Country | Link |
---|---|
US (2) | US11634487B2 (en) |
EP (4) | EP3424527A1 (en) |
JP (2) | JP7239575B2 (en) |
CA (2) | CA3070847A1 (en) |
WO (2) | WO2019008129A1 (en) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3424527A1 (en) * | 2017-07-07 | 2019-01-09 | AVA Lifescience GmbH | Diagnostic method |
WO2020221463A1 (en) * | 2019-05-02 | 2020-11-05 | Ava Lifescience Gmbh | Method for selecting biological binding molecules |
CA3148214A1 (en) * | 2019-05-02 | 2020-11-05 | Ava Lifescience Gmbh | Antigent binding domains and uses therefor |
EP3733709A1 (en) * | 2019-05-02 | 2020-11-04 | AVA Lifescience | Biological binding molecules |
WO2023152204A1 (en) | 2022-02-10 | 2023-08-17 | Ava Lifescience Gmbh | Antibodies targeting the b-cell receptor of chronic lymphocytic leukemia (cll) for use in treatment of cll |
EP4227321A1 (en) | 2022-02-10 | 2023-08-16 | AVA Lifescience GmbH | Antibodies targeting the b-cell receptor of chronic lymphocytic leukemia (cll) for use in treatment of cll |
WO2024023124A1 (en) * | 2022-07-25 | 2024-02-01 | Ava Lifescience Gmbh | Humanized chimeric antigen receptors targeting the b-cell receptor of chronic lymphocytic leukemia and uses thereof |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7393531B2 (en) * | 2003-01-21 | 2008-07-01 | Arius Research Inc. | Cytotoxicity mediation of cells evidencing surface expression of MCSP |
CN104334580B (en) | 2012-02-24 | 2018-03-30 | 艾伯维施特姆森特克斯有限责任公司 | Anti- SEZ6 antibody and application method |
US9770504B2 (en) * | 2013-05-03 | 2017-09-26 | The Board Of Regents Of The University Of Texas System | Generating peptoid vaccines |
AU2014312215B2 (en) * | 2013-08-28 | 2020-02-27 | Abbvie Stemcentrx Llc | Site-specific antibody conjugation methods and compositions |
EP3424527A1 (en) * | 2017-07-07 | 2019-01-09 | AVA Lifescience GmbH | Diagnostic method |
-
2018
- 2018-03-19 EP EP18162666.4A patent/EP3424527A1/en not_active Withdrawn
- 2018-03-19 EP EP18162672.2A patent/EP3424528A1/en not_active Withdrawn
- 2018-07-05 CA CA3070847A patent/CA3070847A1/en active Pending
- 2018-07-05 WO PCT/EP2018/068317 patent/WO2019008129A1/en unknown
- 2018-07-05 WO PCT/EP2018/068316 patent/WO2019008128A1/en unknown
- 2018-07-05 US US16/625,754 patent/US11634487B2/en active Active
- 2018-07-05 JP JP2020522785A patent/JP7239575B2/en active Active
- 2018-07-05 EP EP18746103.3A patent/EP3615072A1/en active Pending
- 2018-07-05 EP EP18746104.1A patent/EP3615073A1/en active Pending
- 2018-07-05 US US16/625,756 patent/US11591391B2/en active Active
- 2018-07-05 CA CA3070848A patent/CA3070848A1/en active Pending
- 2018-07-05 JP JP2020522786A patent/JP7271532B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
US11634487B2 (en) | 2023-04-25 |
JP2020527727A (en) | 2020-09-10 |
JP7271532B2 (en) | 2023-05-11 |
EP3424527A1 (en) | 2019-01-09 |
CA3070847A1 (en) | 2019-01-10 |
CA3070848A1 (en) | 2019-01-10 |
US20200209246A1 (en) | 2020-07-02 |
WO2019008128A1 (en) | 2019-01-10 |
EP3424528A1 (en) | 2019-01-09 |
US20200199225A1 (en) | 2020-06-25 |
WO2019008129A1 (en) | 2019-01-10 |
JP7239575B2 (en) | 2023-03-14 |
US11591391B2 (en) | 2023-02-28 |
JP2020526590A (en) | 2020-08-31 |
EP3615073A1 (en) | 2020-03-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3615072A1 (en) | Diagnostic method | |
DE69128253T2 (en) | SPECIFIC ANTIBODIES, METHOD FOR THEIR PRODUCTION AND THEIR USE | |
DE60226036T9 (en) | ANTIBODY THAT DETERMINES THE GM1-GANGLIOSID-BOUND AMYLOID-B PROTEIN AND DNA THAT CODES FOR THIS ANTIBODY | |
DE69330523T3 (en) | IMMUNOGLOBULINE WITHOUT LIGHT CHAINS | |
DE3853636T2 (en) | ANTIGENE EPITOPES THAT ARE EXCLUSIVELY ON IGE-CARRYING B-LYMPHOCYTES. | |
DE69730209T2 (en) | Multivalent and multispecific antigen binding protein | |
DE69126607T2 (en) | EXTRA CELLULAR PIECES OF HUMAN IGE IMMUNOGLOBULIN ANCHOR PEPTIDES AND SPECIFIC ANTIBODIES THEREFOR | |
EP0531300B1 (en) | Variant cd44 surface proteins, dna sequences coding them, antibodies against these proteins and their use in diagnosis and therapy | |
DE4118120A1 (en) | TETRAVALENT BISPECIFIC RECEPTORS, THEIR PRODUCTION AND USE | |
DE60224200T2 (en) | ASSAY PROCEDURE FOR ALZHEIMER DISEASE | |
DE69333039T2 (en) | MONOCLONAL ANTIBODY AGAINST A HUMAN MDR1 GENE PRODUCT THAT GENERATES RESISTANCE TO VARIOUS MEDICINES AND ITS USE | |
DE69634092T2 (en) | PREPARATION OF ANTIBODIES | |
DE60129278T2 (en) | Antibodies directed against the SEMP1 protein, process for their preparation, and their uses | |
WO2020221466A1 (en) | Biological binding molecules | |
EP3899536B1 (en) | Method for selecting biological binding molecules | |
EP3543697B1 (en) | Method for the selection of biological binding molecules | |
EP0585570B1 (en) | Antigranulocyte antibody construct, preparation and use thereof | |
DE10210427A1 (en) | Human monoclonal antibody | |
US20240002500A1 (en) | Anti-TIGIT Antibody or Antigen-Binding Fragment Thereof | |
EP0537489B1 (en) | Monoclonal antibodies against tumor-associated antigens, method for their preparation and their use | |
WO2020221463A1 (en) | Method for selecting biological binding molecules | |
EP3733709A1 (en) | Biological binding molecules | |
EP0115062A2 (en) | Monoclonal antibody specific for human blood group antigen D (Rh0), and reactive in a direct agglutination test, and hybridoma cell lines procuding these monoclonal antibodies | |
DE69133287T2 (en) | COMPOSED ANTIBODIES BINDING TO DAY-72 WITH THE HUMAN LIGHT CHAIN OF SUB-GROUP-IV | |
DE19964044A1 (en) | Identifying peptides which mimic groups of mammalian trophoblasts |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: UNKNOWN |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20191126 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
17Q | First examination report despatched |
Effective date: 20210819 |
|
19A | Proceedings stayed before grant |
Effective date: 20230512 |
|
RAP3 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: AVA LIFESCIENCE GMBH |